Physician profile

Rajiv Singh

Neurology (Psychiatry & Neurology) · South Miami, FL

NPI 1023451770

$1,891.31

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

See the full distribution for Neurology (Psychiatry & Neurology)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$124.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ucb, INC. $475.79 2019-2023 Briviact
Amgen INC. $312.45 2019-2020
Biogen, INC. $234.57 2019
Acadia Pharmaceuticals INC $192.06 2019-2020
Teva Pharmaceuticals USA, INC. $187.50 2019
Mdd US Operations, LLC $148.85 2019
Emd Serono, INC. $122.37 2019-2020
Genzyme Corporation $115.97 2019
Lilly USA, LLC $63.35 2019-2020
Nuvasive, INC. $21.84 2019
Acorda Therapeutics, INC $16.56 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rajiv Singh

$1,891.31

in general payments reported 2019-2025

Years
2019-2023
Top company
Ucb, INC.

https://glasscript.com/doctor/2784229/rajiv-singh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.